<?xml version="1.0" encoding="UTF-8"?>
<p id="par0260">Tocilizumab is a monoclonal antibody (mAb) that inhibits the IL-6 Receptor. As mentioned earlier, IL-6 plays a key role in respiratory viral infections and in CRS which is linked to poorer prognosis and higher mortality rate in COVID-19 patients. Tocilizumab is approved for the treatment of rheumatoid arthritis and its safety and efficacy profile has previously been well studied [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0370" ref-type="bibr">74</xref>].
</p>
